Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Terumo posts record revenue of 1.1 trillion yen in fiscal 2025

In the fiscal year 2025, which ended in March 2026, Terumo posted its fifth consecutive record revenue at 1.1 trillion yen (+9%) and an operating income of 176.3 billion yen. Adjusted operating income was 219.4 billion yen; margins remained strong despite one-off charges in Q4. Management expects higher operating margins of 20%+ for 2026 and cites the removal of one-off charges, expansion of the neurovascular business and manufacturing optimizations as drivers for further profit growth. Risks include macroeconomic pressure, tariffs, supply-chain disruptions and raw material costs; the stock reacted with a slight decline of 0.41%. » More on de.investing.com
Terumo posts record revenue in Q3 FY2025 thanks to North America, shares fall

Terumo reported its highest quarterly revenue in company history for Q3 FY2025 of JPY 2.966 billion (+13% y/y) and year-to-date revenue of JPY 8.316 billion (+8%). Adjusted operating profit for the first three quarters rose to JPY 1.735 billion (+9%) with a margin of 20.9%, while free cash flow plunged to JPY -1.738 billion. Growth drivers were North America and the Cardiac and Vascular (notably TIS) and Blood and Cell Technologies segments; the acquisition of OrganOx made a significant contribution. Despite the strong figures, the stock fell 2.87%—investors are concerned about ongoing tariffs, inflationary pressure and the sustainability of price measures. » More on de.investing.com
Terumo posts record revenue and strong profit growth in Q2 FY2025

Terumo reported record revenue of ¥534.9 billion (+5%) for the first half and marked profit growth: operating income ¥101.0 billion (+15%), adjusted operating income ¥114.4 billion (+10%) and net profit ¥76.9 billion (+22%). The drivers were mainly strong sales in North America, notably the Cardiac and Vascular segment; management cited price measures and cost control as margin supports. Free cash flow fell 50% to ¥31.0 billion due to higher investments and the acquisition of OrganOx, while guidance for revenue and adjusted operating income was raised. The stock dipped slightly after earnings per share narrowly missed expectations (¥23.76 vs. ¥24.07). » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Terumo has already paid €0.0811 in dividends. The last payout was in June.

Financials

In the last quarter, Terumo had revenue of €1.68B and net profit of €379.41M

(EUR)	June 2026	YoY
Revenue	1.68B	9.53%
Gross profit	961.85M	12.08%
Net profit	379.41M	53.70%
EBITDA	517.34M	12.51%

Fundamentals

Metric	Value
Market capitalization	€20.05B
Number of shares	1.48B
52-week high/low	€15.20 - €10.74
Dividend yield	1.23%
Dividends TTM	€0.16
Next dividend	€0.10
Beta	0.23
P/E ratio	21.57
PEG ratio	0.68
P/B ratio	2.13
P/S ratio	3.00

Company profile

Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

Name	Terumo
CEO	Hikaru Samejima
Headquarters	Tokyo, ty Japan
Website	terumo.co.jp
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	01/04/2000
Employees	31,185